Related Experiment Videos
Mannitol therapy in perinatal hypoxic-ischemic brain damage in rats
D J Mujsce1, J Towfighi, D Stern
1Departments of Pediatrics, Neonatology, Pennsylvania State University School of Medicine, Milton S. Hershey Medical Center, Hershey 17033.
Stroke
|August 1, 1990
Summary
Mannitol effectively reduces brain swelling (cerebral edema) in newborn rats after oxygen deprivation. However, this treatment did not prevent long-term brain damage in this study.
Area of Science:
- Neuroscience
- Pharmacology
- Pediatrics
Background:
- Perinatal hypoxia-ischemia is a major cause of brain injury in newborns.
- Cerebral edema is a significant complication that can worsen neurological outcomes.
- Mannitol is a hyperosmolar agent often used to reduce intracranial pressure and edema.
Purpose of the Study:
- To evaluate the efficacy of mannitol in mitigating cerebral edema.
- To assess the impact of mannitol on neuropathologic outcomes following perinatal hypoxia-ischemia.
- To determine if mannitol improves ultimate brain damage in a rat model.
Main Methods:
- A rat model of perinatal hypoxia-ischemia was established using 7-day postnatal rats.
- Animals received mannitol (4 mg/kg) or saline/no therapy post-insult.
- Brain water content and neuropathologic alterations were assessed 48 hours after hypoxia-ischemia.
Main Results:
- Mannitol significantly reduced brain water content in both ipsilateral and contralateral hemispheres (p < 0.001).
- Mannitol therapy did not alter the incidence, distribution, or severity of brain tissue injury.
- Serum osmolality increased significantly in healthy rats treated with mannitol.
Conclusions:
- Mannitol effectively reduces cerebral edema following perinatal hypoxia-ischemia in rats.
- Despite reducing edema, mannitol did not provide a beneficial effect on ultimate brain damage.
- Further research may be needed to explore alternative or adjunctive therapies for hypoxic-ischemic brain injury.